Amylin/Lilly Byetta Clears FDA As Adjunct Diabetes Therapy; Launch Is June
Executive Summary
Amylin and Lilly will launch the incretin mimetic Byetta (exenatide) for the adjunctive treatment of type 2 diabetes June 1
You may also be interested in...
Lilly Is Reinvesting In Diabetes, Injecting New Life Into Humalog Franchise
Lilly is striving to reenergize its Humalog franchise in 2006 through a pending line extension and an expansion of its insulin production capacity, as the company seeks to rebuild its traditional strength in the diabetes category
Lilly Is Reinvesting In Diabetes, Injecting New Life Into Humalog Franchise
Lilly is striving to reenergize its Humalog franchise in 2006 through a pending line extension and an expansion of its insulin production capacity, as the company seeks to rebuild its traditional strength in the diabetes category
Amylin Agrees To Symlin Marketing Restrictions In Gaining FDA Approval
Amylin has agreed to a ban on direct-to-consumer advertising and other marketing restrictions for its diabetes therapy Symlin (pramlintide) as part of FDA's March 16 approval of the drug